Ancient herb granule takes on MS in new clinical trial
NCT ID NCT07029867
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests whether a traditional Chinese medicine called Yishen Daluo Yin granule can help people with relapsing-remitting multiple sclerosis. About 152 participants will take either the granule or a placebo twice a day for 24 weeks. The main goal is to see if the treatment reduces new brain lesions and relapses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Yishen Daluo Yin granule (a traditional Chinese medicine)
What this could lead to
If it works, this could offer a new treatment option for people with relapsing-remitting multiple sclerosis to reduce brain lesions and relapses.
What could go wrong
This is an early-stage trial with 152 participants, so results may not apply to everyone. The treatment is a traditional Chinese medicine, and its effectiveness and safety are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSE REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.